Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Stopped FDA approved higher dose of study drug. Dose used in protocol lower than SOC - enrollment stopped, those on treatment were given option to opt out.

Conditions

• Metastatic Breast Cancer

Interventions

• DRUG: Fulvestrant
• DRUG: erlotinib
• DRUG: Fulvestrant
• DRUG: Placebo

Sponsor

University of Arkansas

Collaborators

• [object Object]